
|Videos|August 6, 2021
Dr. Ketan K. Badani discusses the significance of PSMA agents
Author(s)Urology Times staff
“I think as these [advanced imaging] agents come out, we're going to see more and more data on this topic,” says Ketan K. Badani, MD.
Advertisement
In this video, Ketan K. Badani, MD, shares a key takeaway in prostate cancer from the 2021 ASCO annual meeting. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
2
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
3
The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C
4
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
5










